MOH
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Ref P/E 16.83, PEG 1.49, Graham Number $126.9
- Low P/S ratio
- P/E is moderate at 16.83
- Price exceeds Graham Number ($126.9)
- Price is 140% above Intrinsic Value ($62.79)
Ref Growth rates and 10-K risk factors
- New contract wins in Florida and Wisconsin
- YoY EPS growth of -154.5%
- Negative operating margins
Ref Historical trends and Earnings track record
- Historical revenue growth
- 1Y return of -50%
- Average surprise of -325.05% over last 4 quarters
Ref Piotroski F-Score 5/9
- Piotroski F-Score 5/9 (Stable)
- Current Ratio 1.69
- Negative operating margin
- Declining net income ($1.18B to $472M)
Ref Yield N/A
- No dividend paid
- 0/100 Dividend Strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for MOH and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
MOH
Molina Healthcare, Inc.
Primary
|
-40.4% | -45.2% | -50.0% | -23.3% | +11.7% | +2.4% |
|
BIO
Bio-Rad Laboratories, Inc.
Peer
|
-49.6% | -35.1% | -15.9% | +12.3% | -1.7% | -5.4% |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
Peer
|
-23.4% | +107.3% | +265.3% | +85.2% | -10.6% | -8.0% |
|
HALO
Halozyme Therapeutics, Inc.
Peer
|
+57.9% | +84.6% | +17.5% | +5.8% | +2.0% | +5.2% |
|
AVTR
Avantor, Inc.
Peer
|
-61.5% | -48.8% | -46.0% | -17.0% | +4.6% | -3.0% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
MOH
Molina Healthcare, Inc.
|
BEARISH | $7.87B | 16.83 | 11.0% | 1.1% | $151.0 | |
|
BIO
Bio-Rad Laboratories, Inc.
|
NEUTRAL | $8.0B | - | -9.5% | -26.4% | $296.57 | Compare |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
BULLISH | $7.71B | 34.41 | 75.5% | 18.5% | $55.05 | Compare |
|
HALO
Halozyme Therapeutics, Inc.
|
NEUTRAL | $8.03B | 26.49 | 153.6% | 22.7% | $67.82 | Compare |
|
AVTR
Avantor, Inc.
|
BEARISH | $8.05B | - | -1.5% | -1.2% | $11.8 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-01 | ORLANDO STEVEN J | Director | Stock Award | 405 | $55,007 |
| 2026-04-01 | WOLF DALE B | Director | Stock Award | 405 | $55,007 |
| 2026-04-01 | GROHOWSKI LEO P | Director | Stock Award | 405 | $55,007 |
| 2026-04-01 | ZORETIC RICHARD C | Director | Stock Award | 405 | $55,007 |
| 2026-04-01 | SCHAPIRO RICHARD M | Director | Stock Award | 405 | $55,007 |
| 2026-04-01 | LOCKHART STEPHEN H | Director | Stock Award | 405 | $55,007 |
| 2026-04-01 | ROMNEY RONNA E | Director | Stock Award | 405 | $55,007 |
| 2026-04-01 | BRASIER BARBARA L. | Director | Stock Award | 405 | $55,007 |
| 2026-03-12 | ROMNEY RONNA E | Director | Sale | 506 | $74,342 |
| 2026-02-27 | HEBERT MAURICE S | Officer | Stock Award | 2,708 | $400,086 |
| 2026-02-27 | BARLOW JEFF D | Officer | Stock Award | 13,722 | $1,999,982 |
| 2026-02-27 | KEIM MARK LOWELL | Chief Financial Officer | Stock Award | 26,073 | $3,800,140 |
| 2026-02-27 | WOYS JAMES E | Chief Operating Officer | Stock Award | 17,016 | $2,480,082 |
| 2026-02-27 | BACON DEBRA | Officer | Stock Award | 9,606 | $1,400,074 |
| 2026-02-27 | ZUBRETSKY JOSEPH M. | Chief Executive Officer | Stock Award | 66,417 | $9,680,278 |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
Molina Healthcare reported 2025 total revenue of $45.4 billion, a 12% increase, though net income declined significantly to $472 million from $1.18 billion in 2024. This decline was driven by a rising medical care ratio of 91.7% and a slight membership decrease to 5.5 million due to Medicaid redeterminations. The company faces primary risks from rising medical care costs and the possibility that state Medicaid reimbursement rates may be insufficient to cover these expenses.
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning MOH from our newsroom.